EMA Reflection Paper on risk based Quality Management in Clinical Trials
The European Medicines Agency EMA has recently released a draft reflection paper on risk based quality management in clinical trials.
The purpose of this reflection paper is to facilitate the development of a more systematic, prioritised, risk-based approach to quality management of clinical trials, to support the principles of Good Clinical Practice and to complement existing quality practices, requirements and standards.
Please also see the reflection paper available for consultation for further details.
Comments related to this reflection paper should be provided using this template. The completed comments form should be sent to GCP@ema.europa.eu.
Please note that the deadline for comments for this reflection paper is 15 February 2012.
Related GMP News
03.04.2025Update on the ICH M11 CeSHArP Technical Specification
03.04.2025EU Map to Clinical Trials
03.04.2025EMA Concept Paper on Model Informed Drug Development
20.03.2025End of the Transition Period for Clinical Trials
11.02.2025Final ICH E6(R3) Guideline on GCP released
11.02.2025FDA issues Draft Guidance on Handling Protocol Deviations in Clinical Trials